Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
1978-8-28
pubmed:abstractText
1. The following four intravenous treatments were administered in a balanced, randomized, Latin square design to four healthy volunteers: (1) saline injection (10 min); salbutamol infusion (0.15 microgram kg-1 min-1 for 60 min) (sS), (2) propranolol injection (0.3 mg kg-1 for 10 min); salbutamol infusion (pS), (3) practolol injection (2 mg kg-1 for 10 min); salbutamol infusion (PS) and (4) saline injection; saline infusion (ss). 2. Heart rate was recorded and venous blood taken for estimation of insulin, glucose and potassium before and after each injection (0 and 12-15 min) and at various times during the infusion (30,45,60 and 75 min). 3. The mean, peak % heart rate changes from baseline, control were +65.8%, +23.0%, -10.9% and -12.1%, the mean, peak % glucose changes, +61.0%, +7.1%, +3.6% and +6.9%, and the mean, peak % insulin changes, +298%, +28%, -28% and -43% during the infusions for sS, PS, ss and pS respectively. 4. The mean serum potassium levels before the injections and at the completion of the infusions were 3.98 and 3.08 4.03 and 3.63, 4.07 and 4.15, and 4.03 and 4.13 meq/l for sS, PS, ss and pS respectively. 5. Propanolol completely abolished the cardiac and metabolic responses of salbutamol. 6. Practolol produced only partial cardiac beta-adrenoceptor blockade, but completely inhibited the metabolic actions of salbutamol.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/207295-1106817, http://linkedlifedata.com/resource/pubmed/commentcorrection/207295-1109657, http://linkedlifedata.com/resource/pubmed/commentcorrection/207295-1114148, http://linkedlifedata.com/resource/pubmed/commentcorrection/207295-1139193, http://linkedlifedata.com/resource/pubmed/commentcorrection/207295-1234013, http://linkedlifedata.com/resource/pubmed/commentcorrection/207295-1234014, http://linkedlifedata.com/resource/pubmed/commentcorrection/207295-1247857, http://linkedlifedata.com/resource/pubmed/commentcorrection/207295-240780, http://linkedlifedata.com/resource/pubmed/commentcorrection/207295-4144507, http://linkedlifedata.com/resource/pubmed/commentcorrection/207295-4384337, http://linkedlifedata.com/resource/pubmed/commentcorrection/207295-4397807, http://linkedlifedata.com/resource/pubmed/commentcorrection/207295-4413622, http://linkedlifedata.com/resource/pubmed/commentcorrection/207295-4425917, http://linkedlifedata.com/resource/pubmed/commentcorrection/207295-4843476, http://linkedlifedata.com/resource/pubmed/commentcorrection/207295-4877600, http://linkedlifedata.com/resource/pubmed/commentcorrection/207295-4928263, http://linkedlifedata.com/resource/pubmed/commentcorrection/207295-5335536, http://linkedlifedata.com/resource/pubmed/commentcorrection/207295-55532, http://linkedlifedata.com/resource/pubmed/commentcorrection/207295-5673352, http://linkedlifedata.com/resource/pubmed/commentcorrection/207295-764913
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
0306-5251
pubmed:author
pubmed:issnType
Print
pubmed:volume
5
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
207-11
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed:year
1978
pubmed:articleTitle
Characterization of beta-adrenoceptor subtype mediating the metabolic actions of salbutamol.
pubmed:publicationType
Journal Article, Clinical Trial, Comparative Study, Randomized Controlled Trial